How does pneumatic tube transportation of thrombocyteconcentrates for transfusion purposes influence the thrombocyte in vivo function?

How does pneumatic tube transportation of thrombocyteconcentrates for transfusion purposes influence the thrombocyte in vivo function? - Thrombocyteconcentrate in vivo function after transportation.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55358

Enrollment

Registered

2014-09-12

Start date

2015-03-24

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lack of bloodplatelets thrombocytopenia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: thrombocytopenia (

Exclusion criteria

Exclusion criteria: Infection and sepsis, active bleeding, splenomegaly Treatment with anticoagulants (LMWH, acetylic acid, coumarines) Thrombocyte transfusion shorter than 72 hours ago Temperature above 37.9 degrees Celsius

Design outcomes

Primary

Measure	Time frame
Increment of transfuion after 1 and 24 hours (measured by number of thrombocytes and corrected ammount increment-CCI) Differences of Mean platelet volume (MPV) Whole blood impedance measurement (activated by ADP/TRAP/COLL/ASPI) CD62 Microparticles PFA-100 Thrombelastography (for fibrinolysis)	—

Secondary

Measure	Time frame
Incidence of spontaneous bleeding irrespective TC transfusion.	—

Countries

Netherlands

Outcome results